Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 344

1.

Establishing key criteria to define and compare models of specialist palliative care: A mixed-methods study using qualitative interviews and Delphi survey.

Firth AM, O'Brien SM, Guo P, Seymour J, Richardson H, Bridges C, Hocaoglu MB, Grande G, Dzingina M, Higginson IJ, Murtagh FE.

Palliat Med. 2019 Jun 28:269216319858237. doi: 10.1177/0269216319858237. [Epub ahead of print]

PMID:
31250704
2.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM.

Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.

3.

Patient perspectives on the linkage of health data for research: Insights from an online patient community questionnaire.

O'Brien EC, Rodriguez AM, Kum HC, Schanberg LE, Fitz-Randolph M, O'Brien SM, Setoguchi S.

Int J Med Inform. 2019 Jul;127:9-17. doi: 10.1016/j.ijmedinf.2019.04.003. Epub 2019 Apr 6.

4.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A.

Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336.

5.

Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S, Eruslanov EB, Moon EK, Albelda SM.

Cancer Immunol Res. 2019 Jun;7(6):896-909. doi: 10.1158/2326-6066.CIR-18-0713. Epub 2019 May 3.

PMID:
31053597
6.

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S.

J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17.

PMID:
30995176
7.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
8.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS.

Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.

PMID:
30920645
9.

Refining The Society of Thoracic Surgeons Congenital Heart Surgery Database Mortality Risk Model With Enhanced Risk Adjustment for Chromosomal Abnormalities, Syndromes, and Noncardiac Congenital Anatomic Abnormalities.

Jacobs JP, O'Brien SM, Hill KD, Kumar SR, Austin EH 3rd, Gaynor JW, Gruber PJ, Jonas RA, Pasquali SK, Pizarro C, St Louis JD, Meza J, Thibault D, Shahian DM, Mayer JE Jr, Jacobs ML.

Ann Thorac Surg. 2019 Mar 7. pii: S0003-4975(19)30266-8. doi: 10.1016/j.athoracsur.2019.01.069. [Epub ahead of print]

PMID:
30853592
10.

Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial.

Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Alexander KP, Senior R, Boden WE, Stone GW, Goodman SG, Lopes RD, Lopez-Sendon J, White HD, Maggioni AP, Shaw LJ, Min JK, Picard MH, Berman DS, Chaitman BR, Mark DB, Spertus JA, Cyr DD, Bhargava B, Ruzyllo W, Wander GS, Chernyavskiy AM, Rosenberg YD, Maron DJ; ISCHEMIA Research Group.

JAMA Cardiol. 2019 Feb 27. doi: 10.1001/jamacardio.2019.0014. [Epub ahead of print]

PMID:
30810700
11.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

12.

Variation in Gastrostomy Tube Placement in Premature Infants in the United States.

Greene NH, Greenberg RG, O'Brien SM, Kemper AR, Miranda ML, Clark RH, Smith PB.

Am J Perinatol. 2018 Dec 21. doi: 10.1055/s-0038-1676591. [Epub ahead of print]

PMID:
30577056
13.

Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.

Thourani VH, O'Brien SM, Kelly JJ, Cohen DJ, Peterson ED, Mack MJ, Shahian DM, Grover FL, Carroll JD, Brennan JM, Forcillo J, Arnold SV, Vemulapalli S, Fitzgerald S, Holmes DR, Bavaria JE, Edwards FH.

Ann Thorac Surg. 2019 Apr;107(4):1097-1103. doi: 10.1016/j.athoracsur.2018.11.013. Epub 2018 Dec 7.

PMID:
30529671
14.

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA.

Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.

15.

Clinical implications of the 2018 iwCLL Guidelines update.

O'Brien SM.

Clin Adv Hematol Oncol. 2018 Aug;16 Suppl 15(8):1-16. Review. No abstract available.

PMID:
30300339
16.

Highlights in chronic lymphocytic leukemia from the 2018 American Society of Clinical Oncology Annual Meeting: commentary.

O'Brien SM.

Clin Adv Hematol Oncol. 2018 Jul;16 Suppl 12(7):14-15. No abstract available.

PMID:
30235180
17.

Development of a Congenital Heart Surgery Composite Quality Metric: Part 2-Analytic Methods.

O'Brien SM, Jacobs JP, Shahian DM, Jacobs ML, Gaynor JW, Romano JC, Gaies MG, Hill KD, Mayer JE, Pasquali SK.

Ann Thorac Surg. 2019 Feb;107(2):590-596. doi: 10.1016/j.athoracsur.2018.07.036. Epub 2018 Sep 15.

18.

Development of a Congenital Heart Surgery Composite Quality Metric: Part 1-Conceptual Framework.

Pasquali SK, Shahian DM, O'Brien SM, Jacobs ML, Gaynor JW, Romano JC, Gaies MG, Hill KD, Mayer JE, Jacobs JP.

Ann Thorac Surg. 2019 Feb;107(2):583-589. doi: 10.1016/j.athoracsur.2018.07.037. Epub 2018 Sep 15.

19.

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design.

Bangalore S, Maron DJ, Fleg JL, O'Brien SM, Herzog CA, Stone GW, Mark DB, Spertus JA, Alexander KP, Sidhu MS, Chertow GM, Boden WE, Hochman JS; ISCHEMIA-CKD Research Group.

Am Heart J. 2018 Nov;205:42-52. doi: 10.1016/j.ahj.2018.07.023. Epub 2018 Aug 1.

20.

The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2018 Update on Research.

Jacobs ML, Jacobs JP, Hill KD, O'Brien SM, Pasquali SK, Vener D, Kumar SR, Chiswell K, Habib RH, Shahian DM, Fernandez FG.

Ann Thorac Surg. 2018 Sep;106(3):654-663. doi: 10.1016/j.athoracsur.2018.06.032. Epub 2018 Jul 25.

PMID:
30055139
21.

National Benchmarks for Proportions of Patients Receiving Blood Transfusions During Pediatric and Congenital Heart Surgery: An Analysis of the STS Congenital Heart Surgery Database.

Kartha VM, Jacobs JP, Vener DF, Hill KD, Goldenberg NA, Pasquali SK, Meza JM, O'Brien SM, Feng L, Chiswell K, Eghtesady P, Badhwar V, Rehman M, Jacobs ML.

Ann Thorac Surg. 2018 Oct;106(4):1197-1203. doi: 10.1016/j.athoracsur.2018.04.088. Epub 2018 Jun 11.

PMID:
29902465
22.

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.

Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, Heerema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM.

Br J Haematol. 2018 Aug;182(4):504-512. doi: 10.1111/bjh.15421. Epub 2018 Jun 5.

23.

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design.

ISCHEMIA Trial Research Group, Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, Williams DO, Harrington RA, Rosenberg Y.

Am Heart J. 2018 Jul;201:124-135. doi: 10.1016/j.ahj.2018.04.011. Epub 2018 Apr 21. Review.

24.

The Impact of Mitral Disease Etiology on Operative Mortality After Mitral Valve Operations.

Rankin JS, Grau-Sepulveda M, Shahian DM, Gillinov AM, Suri R, Gammie JS, Bolling SF, McCarthy PM, Thourani VH, Ad N, O'Brien SM, Jacobs JP, Badhwar V.

Ann Thorac Surg. 2018 Nov;106(5):1406-1413. doi: 10.1016/j.athoracsur.2018.04.053. Epub 2018 May 16.

PMID:
29777670
25.

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.

Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG.

Leukemia. 2018 Nov;32(11):2388-2398. doi: 10.1038/s41375-018-0132-y. Epub 2018 Apr 17.

26.

ISCHEMIA: Establishing the Primary End Point.

Bangalore S, Maron DJ, Reynolds HR, Stone GW, O'Brien SM, Alexander KP, Hochman JS.

Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004791. doi: 10.1161/CIRCOUTCOMES.118.004791. No abstract available.

27.

Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting: commentary.

O'Brien SM.

Clin Adv Hematol Oncol. 2018 Jan;16 Suppl 2(1):16-19. No abstract available.

PMID:
29742092
28.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.

Cancer. 2018 Jun 15;124(12):2534-2540. doi: 10.1002/cncr.31370. Epub 2018 Apr 12.

29.

The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 1-Background, Design Considerations, and Model Development.

Shahian DM, Jacobs JP, Badhwar V, Kurlansky PA, Furnary AP, Cleveland JC Jr, Lobdell KW, Vassileva C, Wyler von Ballmoos MC, Thourani VH, Rankin JS, Edgerton JR, D'Agostino RS, Desai ND, Feng L, He X, O'Brien SM.

Ann Thorac Surg. 2018 May;105(5):1411-1418. doi: 10.1016/j.athoracsur.2018.03.002. Epub 2018 Mar 22.

PMID:
29577925
30.

The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 2-Statistical Methods and Results.

O'Brien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, Kurlansky PA, Furnary AP, Cleveland JC Jr, Lobdell KW, Vassileva C, Wyler von Ballmoos MC, Thourani VH, Rankin JS, Edgerton JR, D'Agostino RS, Desai ND, Edwards FH, Shahian DM.

Ann Thorac Surg. 2018 May;105(5):1419-1428. doi: 10.1016/j.athoracsur.2018.03.003. Epub 2018 Mar 22.

PMID:
29577924
31.

Inclusion of Functional Status Measures in the Risk Adjustment of 30-Day Mortality After Transcatheter Aortic Valve Replacement: A Report From the Society of Thoracic Surgeons/American College of Cardiology TVT Registry.

Arnold SV, O'Brien SM, Vemulapalli S, Cohen DJ, Stebbins A, Brennan JM, Shahian DM, Grover FL, Holmes DR, Thourani VH, Peterson ED, Edwards FH; STS/ACC TVT Registry.

JACC Cardiovasc Interv. 2018 Mar 26;11(6):581-589. doi: 10.1016/j.jcin.2018.01.242.

32.

Development and validation of a casemix classification to predict costs of specialist palliative care provision across inpatient hospice, hospital and community settings in the UK: a study protocol.

Guo P, Dzingina M, Firth AM, Davies JM, Douiri A, O'Brien SM, Pinto C, Pask S, Higginson IJ, Eagar K, Murtagh FEM.

BMJ Open. 2018 Mar 17;8(3):e020071. doi: 10.1136/bmjopen-2017-020071.

33.

Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.

Choudhry A, O'Brien SM.

Drugs Today (Barc). 2017 Dec;53(12):653-665. doi: 10.1358/dot.2017.53.12.2737934.

PMID:
29517084
34.

Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.

Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z.

Leukemia. 2018 Oct;32(10):2278-2281. doi: 10.1038/s41375-018-0059-3. Epub 2018 Feb 20. No abstract available.

PMID:
29479067
35.

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE.

JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604.

36.

Single- Versus Multicenter Surgeons' Risk-Adjusted Coronary Artery Bypass Graft Procedural Outcomes.

Shroyer ALW, Gioia WE, Bishawi M, Wallace AS, Gulack BC, Xian Y, O'Brien SM, Thourani VH, Bilfinger TV.

Ann Thorac Surg. 2018 May;105(5):1308-1314. doi: 10.1016/j.athoracsur.2018.01.023. Epub 2018 Feb 7.

PMID:
29427617
37.

Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.

Khazanie P, Al-Khatib SM, Wang TY, Crowley MJ, Kressin NR, Krumholz HM, Kiefe CI, Wells BL, O'Brien SM, Peterson ED, Sanders GD.

Am Heart J. 2018 Feb;196:170-177. doi: 10.1016/j.ahj.2017.07.022. Epub 2017 Sep 19.

PMID:
29421010
38.

How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?

Crowley MJ, Al-Khatib SM, Wang TY, Khazanie P, Kressin NR, Krumholz HM, Kiefe CI, Wells BL, O'Brien SM, Peterson ED, Sanders GD.

Am Heart J. 2018 Feb;196:163-169. doi: 10.1016/j.ahj.2017.09.008. Epub 2017 Sep 18. Review.

PMID:
29421009
39.

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR.

Blood Adv. 2016 Dec 27;1(3):250-259. doi: 10.1182/bloodadvances.2016001495.

40.

Pressure and traction on a model fetal head and neck associated with the use of forceps, Kiwi™ ventouse and the BD Odon Device™ in operative vaginal birth: a simulation study.

O'Brien SM, Winter C, Burden CA, Boulvain M, Draycott TJ, Crofts JF.

BJOG. 2017 Sep;124 Suppl 4:19-25. doi: 10.1111/1471-0528.14760.

41.

Design and development of the BD Odon DeviceTM : a human factors evaluation process.

O'Brien SM, Mouser A, Odon JE, Winter C, Draycott TJ, Sumitro T, Alisantoso D, Lim WL, Merialdi M, Stankovic AK, Crofts JF.

BJOG. 2017 Sep;124 Suppl 4:35-43. doi: 10.1111/1471-0528.14758.

42.

Fetal head position and perineal distension associated with the use of the BD Odon Device™ in operative vaginal birth: a simulation study.

O'Brien SM, Winter C, Burden CA, Boulvain M, Draycott TJ, Crofts JF.

BJOG. 2017 Sep;124 Suppl 4:10-18. doi: 10.1111/1471-0528.14759.

43.

Highlights From the XVII International Workshop on Chronic Lymphocytic Leukemia: Commentary.

O'Brien SM.

Clin Adv Hematol Oncol. 2017 Jul;15 Suppl 6(7):13-15. No abstract available.

PMID:
28837123
44.

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.

Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A.

Haematologica. 2017 Dec;102(12):e494-e496. doi: 10.3324/haematol.2017.171561. Epub 2017 Aug 10. No abstract available.

45.

The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2017 Update on Research.

Jacobs ML, Jacobs JP, Hill KD, Hornik C, O'Brien SM, Pasquali SK, Vener D, Kumar SR, Habib RH, Shahian DM, Edwards FH, Fernandez FG.

Ann Thorac Surg. 2017 Sep;104(3):731-741. doi: 10.1016/j.athoracsur.2017.07.001. Epub 2017 Jul 29. Review.

PMID:
28760477
46.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.

Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E.

Leuk Lymphoma. 2018 Apr;59(4):813-820. doi: 10.1080/10428194.2017.1349907. Epub 2017 Jul 18.

47.

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H.

Cancer. 2017 Nov 15;123(22):4430-4439. doi: 10.1002/cncr.30883. Epub 2017 Jul 14.

48.

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI.

Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4.

PMID:
28687420
49.

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM.

Br J Haematol. 2017 Jul;178(2):286-291. doi: 10.1111/bjh.14660. Epub 2017 Apr 10.

50.

Acute lymphoblastic leukemia in adolescents and young adults.

Rytting ME, Jabbour EJ, O'Brien SM, Kantarjian HM.

Cancer. 2017 Jul 1;123(13):2398-2403. doi: 10.1002/cncr.30624. Epub 2017 Mar 22. Review.

Supplemental Content

Loading ...
Support Center